A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

Summary

This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.

Timeline

Start

2022-02-11

Primary completion

2022-08-05

Completion

2022-08-05

Outcome

Outcome not reported

Stopped (Business): “The clinical development strategy has been changed”

Drugs

Indications